1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
2026 cycle: opened March 1, closed May 19, 2026 (extended from May 15). Results expected October 2026. Next cycle Spring 2027.
AMR Research Call is sponsored by Novo Nordisk Foundation. AMR Research Call is a grant program from the Novo Nordisk Foundation under its Infectious Diseases Catalyst Grants initiative, providing catalytic funding for exploratory, use-inspired, and innovative research projects with exceptional potential for direct impact on global chal…
Get alerted about grants like this
Get emailed when new opportunities from “Novo Nordisk Foundation” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Infectious Diseases Catalyst Grants - Novo Nordisk Fonden Infectious Diseases Catalyst Grants 19 May 2026 2:00pm (Copenhagen time) Rules, grant administration and FAQ Projects led by a PI based in a Nordic country can be awarded up to 4 million up to 3 years. Collaborative projects involving a Nordic PI and an international co-applicant can be awarded up to DKK 7 million. International, Nordic Countries (incl.
Denmark) Research Leaders (Established/Prof.), Research Leaders (junior/non-tenured), Research Leaders (Mid-career/Associate Prof.) Bioscience and Basic Biomedicine, Clinical and Translational Medicine, Infectious Diseases Committee for Infectious Diseases (CID) Grant Specialist, Grant Management Please note that the submission deadline has been extended by four days. The new deadline is May 19 at 2pm Danish time.
The purpose of the “Infectious Diseases – Catalyst Grants” programme is to provide catalytic funding for exploratory, use-inspired, and innovative research projects that have exceptional potential for future direct impact on global challenges within human infectious diseases . In 2026, projects submitted to this call for applications must be within one of the two scientific themes , namely Novel AMR tools or Pandemic Influenza .
The main applicant must be anchored and have their primary employment and research group at a university, hospital, or other non-profit research institution in a Nordic country. The main applicant must be employed at the institution they are applying from and must be guaranteed their own salary for the entire project period. The main applicant must be at assistant professor, associate professor, or professor (or similar levels).
Applications from postdocs or Ph. D. students are not accepted.
Early career-stage group-leaders as well as women and other groups that have been historically under-represented in scientific research are strongly encouraged to apply and to be included as co-applicants. A co-applicant can be based anywhere globally, but must be in a different country to the main applicant.
A main applicant (or a co-applicant ) can only submit/be part of one application to the 2026 “Infectious Diseases – Catalyst Grants Call” and cannot be an applicant on a different application. Researchers who hold an active “Infectious Diseases Catalyst Grant” cannot apply until they are in the final year of their existing Catalyst grant, and the grant period for a new project cannot overlap with that of the active grant.
The project must be in scope of at least one of the two 2026 research themes and it must be use-inspired i.e., the research project must enhance fundamental knowledge and include considerations of potential application/translation of the knowledge gained towards generating better and needed tools. The scientific rationale, concept, and research direction should be driven by the potential use and/or translation of that knowledge.
The application should have clear aims/goals, and articulate the expected outcomes catalysed by this project, and the potential future impact of these outcomes beyond this project. The current clinical pipeline for tools to combat antimicrobial resistance (AMR) is inadequate and urgently requires new and innovative solutions.
Projects supported under this theme should investigate rationally designed and novel approaches to prevent, diagnose or treat antimicrobial resistant bacterial infections . Pathogens listed on the WHO Bacterial Priority Pathogen List, 2024 will be prioritised. Theme 2: Pandemic Influenza Pandemic influenza remains a substantial threat to public health.
There is an urgent need for a deeper understanding of the factors that influence viral infectivity, transmission, and disease severity in humans. Projects supported under this theme should address major research gaps in our understanding of pandemic influenza and interactions with the human host and aid the development of tools to prevent or combat infections effectively.
Out of scope : Projects which are mainly focused on surveillance, establishment/maintaining infrastructure (incl. databases and algorithms), clinical trial(s), microbiome research, phage therapy, as well as projects not directly related to human health. For-profit product development projects are ineligible.
A total of DKK 60 million is available for proposals in this call in 2026. The individual grants awarded can have one of two different granting frameworks: For each grant where there is only one applicant who is based in the Nordics, up to DKK 4 million can be awarded, with a grant period of up to 3 years.
For each grant where there is a Nordic main applicant and a co-applicant based in a different country, up to DKK 7 million can be awarded, with a grant period of up to 3 years. The budget does not have to be split evenly between the main and co-applicant institutions, but if one institution will receive significantly more funding, a clear justification must be provided.
The application must be completed and submitted using NNF’s online application and grant management system, NORMA, which can be accessed from: https://norma. novonordiskfonden. dk.
Applications will be assessed by the Committee for Infectious Diseases (CID) When all applications have been assessed, applicants will be notified if they have/ or have not been awarded a grant. The notification e-mail will be sent from norma. novonordiskfonden.
dk to the e-mail address entered on initial registration. For questions addressed in previous years regarding the call, please refer to the FAQ . NNF Kenya A/S Branch Office Studio 608 and 609, 6th floor NNF India A/S Branch Office Data Ethics and AI Policy Ethics in major construction Yes, I would like to receive relevant news from the Novo Nordisk Foundation.
Please enter a valid e-mail address
According to the current listing, eligibility includes: Research institutions, biotech companies worldwide. Confirm the full requirements in the official notice before applying.
The current listing shows $500,000 - $5 million. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The most recent published deadline was May 19, 2026, which has passed. This is an annual program, so a new cycle should follow. The next cycle is expected around March 2027.
AMR Research Call is funded by Novo Nordisk Foundation. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The solicitation lists 3 required documents: Application via NORMA system, Project description, and Budget. Check the official notice for formatting and page-limit rules.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.